TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03819257

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoanal ultrasound
Description: For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution anorectal manometry
Description: 1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension.

Intervention type: DIAGNOSTIC_TEST
Intervention: Balloon expulsion test
Description: A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
Study: NCT01986283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00345439
Description: 40 mg capsule chewed, taken once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: 40 mg solution, taken once
Study: NCT03821883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Tablet
Description: Aspirin 100mg qd
Study: NCT01392378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFANRIX hexa
Description: INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFANRIX hexa
Description: INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Study: NCT03922061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV
Description: fractional-dose inactived polio vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fIPV
Description: fractional-dose inactived polio vaccine
Study: NCT01186159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: 40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
Study: NCT01392378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFANRIX hexa
Description: INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFANRIX hexa
Description: INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Study: NCT00813618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study: NCT02447120

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT machines used for diagnostic purposes
Study: NCT01617655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Study: NCT00889707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Study: NCT00377182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: 1000/1200mg po daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS
Description: 180 micrograms sc weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: 180 micrograms sc weekly for 4 weeks
Study: NCT01617655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT03224585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days
Study: NCT00517283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide and placebo
Description: Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide and placebo
Description: Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide and placebo
Description: Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
Study: NCT01883869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03965793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated management of hypotension
Description: Fluid and vasopressor will be administered based on a novel automated clinical decision support system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated management of hypotension
Description: Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
Study: NCT02633839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Description: Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Description: Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Administered orally according to the carbidopa dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Administered orally according to the carbidopa dosing schedule.
Study: NCT04387526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (SOF and DCV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (SOF, DCV, and RBV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (SOF, DCV, and RBV)
Study: NCT00889707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Study: NCT02590536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03465722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avapritinib
Description: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regorafenib
Description: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
Study: NCT03172273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular intrahepatic portosystemic shunt with covered PTFE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Description: paracentasis plus albumine invision
Study: NCT00527618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: valacyclovir 1000 mg orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: acyclovir 400 mg orally twice daily for 12 weeks.
Study: NCT00363142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-boosted Fosamprenavir
Description: Once daily, reduced dose ritonavir-boosted fosamprenavir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full Boosted Fosamprenavir
Description: Full ritonavir-boosted fosamprenavir
Study: NCT02881775

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS and exercise
Description: rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS and exercise
Description: rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS and exercise
Description: rTMS unit is on and running but mu metal is placed between the coil and the skull

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS and exercise
Description: rTMS unit is on and running but mu metal is placed between the coil and the skull
Study: NCT02267889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image guided GP ablation
Description: 3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-SPECT dedicated cardiac nuclear camera
Study: NCT01655186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00377182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: 180 micrograms sc weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: 180 micrograms sc weekly for 4 weeks
Study: NCT02156024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrodia and Uncaria Drink
Description: Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
Study: NCT01022970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAX576 placebo
Study: NCT01637870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena negative pressure wound system
Description: Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
Study: NCT01244958

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000 mg Rituximab infusion
Study: NCT00377182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048 1500mg
Description: 1500mg po bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048 1500mg
Description: 1500mg po bid for 4 weeks
Study: NCT01244958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion of Sodium citrate, Polysorbate, Sodium chloride
Study: NCT03276013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab in combination with doxorubicin
Study: NCT03427450

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
Study: NCT01993615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Surgery
Description: The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
Study: NCT00377182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048 3000mg
Description: 3000mg po bid for 4 weeks
Study: NCT01661569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headspace On-the-go app
Description: Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
Study: NCT03427632

Intervention type: DRUG
Intervention: Bone Cements
Description: patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
Study: NCT00681603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)
Description: subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
Study: NCT01022970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX576
Study: NCT02570646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QA-DDS
Description: QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
Study: NCT01565590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.2-1.5 mcg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 5-80 mcg/kg/min
Study: NCT03173612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
Study: NCT02485587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Arousal-Biofeedback
Description: biofeedback of biological measures of arousal (electrodermal activity)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: counseling, psychoeducation
Study: NCT06073197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
Study: NCT03171311

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic guided PCI
Description: Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT guided PCI
Description: OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
Study: NCT06073197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined deep and superficial serratus anterior plane block
Description: Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
Study: NCT04545099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Administration of Sugammadex for muscle relaxation reversal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Administration of Neostigmine for muscle relaxation reversal